• glutamate transporter It is an open question if these

  2022-06-20

  

  It is an open question if these in vitro findings have implications for the use of sGC activators in the in vivo situation and in patients. Assuming that incorporation in de novo synthesised enzyme occurs during therapy, one might speculate that the duration of drug administration has an influence o

• Many studies have reported on the

  2022-06-20

  

  Many studies have reported on the association between GST gene polymorphisms and pulmonary disorders but with controversial results [7]. In the present study, on comparing results of GSTP1 gene polymorphism among the studied COPD patient groups, it was found that heterozygote mutation was significa

• Also in this work we investigated the

  2022-06-20

  

  Also in this work, we investigated the correlated signaling pathways of GSK-3 inhibition in protecting bupivacaine-induced DRG neurotoxicity. Through western blot assay, we demonstrated that, SB216763 suppressed protein productions of p-GSK-3 α/β and Casp-3, but increased protein production of PKC,

• Recently the novel fatty acid receptor GPR also called FFAR

  2022-06-20

  

  Recently, the novel fatty IWR-1-endo receptor, GPR120 (also called FFAR4), has been shown to be implicated in diverse physiological homeostasis, such as insulin sensitization, anti-inflammation and regulation of appetite (Hirasawa et al., 2005, Oh et al., 2010). Notably, it is abundantly expressed i

• The importance of FXR FGF signaling in BA

  2022-06-20

  

  The importance of FXR-FGF15/19 signaling in BA homeostasis is illustrated by various BA malabsorption syndromes. Clinically, BA malabsorption causes diarrhea due to high BA concentrations in the colon that lead to secretion of water and electrolytes and stimulation of propulsive contractions [36]. P

• The occurrence of MDR in

  2022-06-20

  

  The occurrence of MDR in cancer patients undergoing chemotherapy can be mimicked in the laboratory by culturing cancer A939572 in the presence of chemotherapeutic drugs, thereby enforcing the evolution of acquired drug resistance. This has been described in multiple model systems including the rhab

• Methods br Results br Discussion In this report the therapeu

  2022-06-18

  

  Methods Results Discussion In this report, the therapeutic effect of a GCGR antagonistic antibody REMD2.59 was tested in 2 mechanistically divergent disease models of heart failure without confounding defects in global metabolism. Based on histological and functional analyses in both MI-injur

• The eradication of agonist activity in compound

  2022-06-18

  

  The eradication of agonist activity in compound was also confirmed in the ex vivo growth hormone (GH) release experiment conducted in isolated primary rat pituitary 5-Methyl-CTP as shown in . Compound did not produce any noticeable GH secretion at up to 10μM concentration. It could also antagoniz

• Somatostatin analogues are among the first

  2022-06-18

  

  Somatostatin analogues are among the first peptide-based drugs used in cancer imaging and therapy (for review see Reubi, 2003). Treatment of tumors by the use of peptide analogues labeled with cytotoxic agents acting via specific receptors is also under investigation for neuropeptide Y (Koglin and B

• Liver is the house for a

  2022-06-18

  

  Liver is the house for a variety of xenobiotic-metabolizing phenylephrine hydrochloride mg that produce reactive oxygen species as well as reactive metabolites (Johansson et al., 2009; Noh et al., 2017; Puntarulo and Cederbaum, 1998). When the enzymes act upon pre- or pro-haptens, the chemicals wou

• br Experimental br Results and

  2022-06-18

  

  Experimental Results and discussions Conclusion Notes Introduction The noncanonical DNA structures that is, i-motif [[1], [2], [3], [4], [5], [6], [7], [8], [9]] and G-quadruplex [[10], [11], [12], [13], [14]] have recently been carefully studied using either experimental or computati

• Acquiring resistance to the FGFR inhibitor

  2022-06-18

  

  Acquiring resistance to the FGFR inhibitor may determine treatment outcomes in patients with GC dependent on FGFR2 amplification, and we investigated the mechanism of AZD4547 resistance in FGFR2-amplified GC cells. We established a FGFR2-amplified GC cell line resistant to the selective FGFR inhibi

• As a part of our

  2022-06-18

  

  As a part of our continuing efforts towards discovery of new class of compounds against different therapeutic areas and based on the literature reports, we designed a dual pharmacophore which possess a long aliphatic chain of free fatty acids and a phenyl propanoid part of known GPR40 agonists. Here

• In this study according to the critical pharmacophore T Y

  2022-06-18

  

  In this study, according to the critical pharmacophore T31, Y113 and R140 of FBPase, using the strategy of pharmacophore-based virtual screening, a series of novel scaffold inhibitor targeted the AMP binding site of FBPase were screened, their inhibitory activities against FBPase were further tested

• Potential platelet related mechanisms that might explain an

  2022-06-18

  

  Potential platelet-related mechanisms that might explain an augmented risk of MI in dabigatran treated patients have been investigated: Enhanced platelet reactivity is known to be associated with the risk of MI (Mangiacapra et al., 2018) and catalytically active thrombin is a potent stimulus to indu

14569 records 409/972 page Previous Next First page 上5页 406407408409410 下5页 Last page